Valuation: EyePoint, Inc.

Market Cap 119.75Cr 103.58Cr 97Cr 89Cr 166.9Cr 11TCr 169.55Cr 1.13TCr 445.44Cr 5.71TCr 449.68Cr 439.84Cr 19TCr P/E 2026 *
-3.61x
P/E 2027 * -4.72x
Enterprise Value 87Cr 76Cr 71Cr 65Cr 121.91Cr 8.32TCr 123.85Cr 828.97Cr 325.37Cr 4.17TCr 328.47Cr 321.28Cr 14TCr EV / Sales 2026 *
476x
EV / Sales 2027 * 32.7x
Free-Float
96.42%
Yield 2026 *
-
Yield 2027 * -
1 day+10.55%
1 week+12.50%
Current month+7.34%
1 month-7.14%
3 months+2.63%
6 months+1.52%
Current year-22.67%
1 week 9.8
Extreme 9.8
11.7
1 month 9.8
Extreme 9.8
12.5
Current year 9.45
Extreme 9.45
15.27
1 year 8.47
Extreme 8.466
15.32
3 years 3.52
Extreme 3.525
28.6
5 years 2.08
Extreme 2.08
28.6
10 years 0.38
Extreme 0.382
35.98
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Change 5-day change 1-year change 3-year change Capi.($)
+10.55%+12.50% - - 119.75Cr
-0.52%+3.21%+89.52%+125.32% 1,05700Cr
+0.88%+1.13%+49.56%+49.79% 62TCr
+0.89%-1.95%+24.23%+63.19% 43TCr
+0.50%+3.62%+49.78%+38.22% 36TCr
-0.21%+1.03%+30.99%+38.86% 30TCr
+0.03%+3.55%+7.90%+6.68% 25TCr
+1.51%+6.69%+42.58%+58.47% 22TCr
-1.03%-0.20%-6.48%-51.65% 21TCr
+1.80%+2.30%+11.56%+66.16% 17TCr
Average +1.42%+0.94%+33.29%+43.89% 40.23TCr
Weighted average by Cap. +0.22%+1.33%+48.43%+63.86%

Financials

2026 *2027 *
Net sales 18.37L 15.89L 14.84L 13.61L 25.61L 17Cr 26.01L 1.74Cr 68.34L 8.76Cr 68.99L 67.48L 29Cr 2.55Cr 2.21Cr 2.06Cr 1.89Cr 3.56Cr 242.88Cr 3.61Cr 24Cr 9.49Cr 121.74Cr 9.58Cr 9.37Cr 402.46Cr
Net income -35Cr -30Cr -28Cr -26Cr -48Cr -3.29TCr -49Cr -327.83Cr -128.67Cr -1.65TCr -129.9Cr -127.05Cr -5.46TCr -29Cr -25Cr -23Cr -21Cr -40Cr -2.74TCr -41Cr -273.33Cr -107.28Cr -1.38TCr -108.3Cr -105.93Cr -4.55TCr
Net Debt -32Cr -28Cr -26Cr -24Cr -45Cr -3.07TCr -46Cr -305.92Cr -120.07Cr -1.54TCr -121.22Cr -118.56Cr -5.09TCr -36Cr -31Cr -29Cr -27Cr -50Cr -3.44TCr -51Cr -343.03Cr -134.64Cr -1.73TCr -135.92Cr -132.95Cr -5.71TCr
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change
10/26/10 11.70 +7.34%
07/26/07 €10.90 +7.92%
06/26/06 €10.10 +2.02%
05/26/05 €9.900 -4.81%
04/26/04 €10.40 0.00%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
13.89USD
Average target price
40.93USD
Spread / Average Target
+194.66%

Quarterly revenue - Rate of surprise